Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer Acetate
Catherine M. Edgar(Kingston General Hospital), Peter Green(Columbia University), Evelyn V. McBride(Queen's University), Paul V. Fenton(Queen's University), Donald Brunet(Queen's University)
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
February 1, 2004
Cited by 64
Related Papers
<scp>SIMR</scp>: an R package for power analysis of generalized linear mixed models by simulation
|Methods in Ecology and Evolution|2015|2.4k
Emotional Reactivity to Everyday Problems, Affective Inertia, and Neuroticism
|Personality and Social Psychology Bulletin|1998|432
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
|The Lancet Neurology|2018|345
Brown-Vialetto-Van Laere Syndrome, a Ponto-Bulbar Palsy with Deafness, Is Caused by Mutations in C20orf54
|The American Journal of Human Genetics|2010|196